Annual Retained Earnings
-$2.01 B
-$444.04 M-28.31%
31 December 2023
Summary:
Iovance Biotherapeutics annual retained earnings is currently -$2.01 billion, with the most recent change of -$444.04 million (-28.31%) on 31 December 2023. During the last 3 years, it has fallen by -$1.18 billion (-142.40%). IOVA annual retained earnings is now -3428136.80% below its all-time high of -$58.70 thousand, reached on 31 December 2008.IOVA Retained Earnings Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Retained Earnings
-$2.31 B
-$83.54 M-3.76%
30 September 2024
Summary:
Iovance Biotherapeutics quarterly retained earnings is currently -$2.31 billion, with the most recent change of -$83.54 million (-3.76%) on 30 September 2024. Over the past year, it has dropped by -$410.00 million (-21.62%). IOVA quarterly retained earnings is now -8572364.68% below its all-time high of -$26.90 thousand, reached on 31 March 2008.IOVA Quarterly Retained Earnings Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
IOVA Retained Earnings Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -28.3% | -21.6% |
| 3 y3 years | -142.4% | -114.9% |
| 5 y5 years | -439.9% | -354.8% |
IOVA Retained Earnings High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -142.4% | at low | -114.9% | at low |
| 5 y | 5 years | -439.9% | at low | -354.8% | at low |
| alltime | all time | <-9999.0% | at low | <-9999.0% | at low |
Iovance Biotherapeutics Retained Earnings History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | -$2.31 B(+3.8%) |
| June 2024 | - | -$2.22 B(+4.6%) |
| Mar 2024 | - | -$2.13 B(+5.6%) |
| Dec 2023 | -$2.01 B(+28.3%) | -$2.01 B(+6.1%) |
| Sept 2023 | - | -$1.90 B(+6.4%) |
| June 2023 | - | -$1.78 B(+6.4%) |
| Mar 2023 | - | -$1.68 B(+6.8%) |
| Dec 2022 | -$1.57 B(+33.8%) | -$1.57 B(+7.2%) |
| Sept 2022 | - | -$1.46 B(+7.3%) |
| June 2022 | - | -$1.36 B(+7.9%) |
| Mar 2022 | - | -$1.26 B(+7.8%) |
| Dec 2021 | -$1.17 B(+41.2%) | -$1.17 B(+9.3%) |
| Sept 2021 | - | -$1.07 B(+8.7%) |
| June 2021 | - | -$986.99 M(+9.0%) |
| Mar 2021 | - | -$905.64 M(+9.1%) |
| Dec 2020 | -$830.19 M(+45.5%) | -$830.19 M(+9.0%) |
| Sept 2020 | - | -$761.80 M(+8.3%) |
| June 2020 | - | -$703.23 M(+9.8%) |
| Mar 2020 | - | -$640.21 M(+12.2%) |
| Dec 2019 | -$570.61 M(+53.1%) | -$570.61 M(+12.5%) |
| Sept 2019 | - | -$507.04 M(+10.8%) |
| June 2019 | - | -$457.56 M(+11.6%) |
| Mar 2019 | - | -$410.01 M(+10.0%) |
| Dec 2018 | -$372.76 M(+49.6%) | -$372.76 M(+9.6%) |
| Sept 2018 | - | -$340.19 M(+11.0%) |
| June 2018 | - | -$306.36 M(+11.1%) |
| Mar 2018 | - | -$275.69 M(+10.6%) |
| Dec 2017 | -$249.18 M(+58.6%) | -$249.18 M(+11.6%) |
| Sept 2017 | - | -$223.33 M(+11.0%) |
| June 2017 | - | -$201.18 M(+13.1%) |
| Mar 2017 | - | -$177.80 M(+13.2%) |
| Dec 2016 | -$157.12 M | -$157.12 M(+11.1%) |
| Sept 2016 | - | -$141.43 M(+15.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| June 2016 | - | -$122.67 M(+10.4%) |
| Mar 2016 | - | -$111.11 M(+6.6%) |
| Dec 2015 | -$104.22 M(+36.1%) | -$104.22 M(+8.7%) |
| Sept 2015 | - | -$95.84 M(+8.6%) |
| June 2015 | - | -$88.23 M(+7.8%) |
| Mar 2015 | - | -$81.86 M(+6.9%) |
| Dec 2014 | -$76.56 M(+18.7%) | -$76.56 M(+6.8%) |
| Sept 2014 | - | -$71.70 M(+4.1%) |
| June 2014 | - | -$68.90 M(+3.2%) |
| Mar 2014 | - | -$66.79 M(+3.5%) |
| Dec 2013 | -$64.53 M(+110.3%) | -$64.53 M(+44.8%) |
| Sept 2013 | - | -$44.57 M(+26.8%) |
| June 2013 | - | -$35.16 M(+10.8%) |
| Mar 2013 | - | -$31.73 M(+3.4%) |
| Dec 2012 | -$30.68 M(+12.1%) | -$30.68 M(-10.1%) |
| Sept 2012 | - | -$34.15 M(+2.0%) |
| June 2012 | - | -$33.48 M(+1.0%) |
| Mar 2012 | - | -$33.15 M(+21.1%) |
| Dec 2011 | -$27.38 M(+1527.1%) | -$27.38 M(+43.9%) |
| Sept 2011 | - | -$19.02 M(+44.1%) |
| June 2011 | - | -$13.21 M(+487.8%) |
| Mar 2011 | - | -$2.25 M(+33.5%) |
| Dec 2010 | -$1.68 M(+2158.4%) | -$1.68 M(+78.9%) |
| Sept 2010 | - | -$940.60 K(+314.7%) |
| June 2010 | - | -$226.80 K(+59.5%) |
| Mar 2010 | - | -$142.20 K(+90.9%) |
| Dec 2009 | -$74.50 K(+26.9%) | -$74.50 K(+3.3%) |
| Sept 2009 | - | -$72.10 K(+4.9%) |
| June 2009 | - | -$68.70 K(+5.2%) |
| Mar 2009 | - | -$65.30 K(+11.2%) |
| Dec 2008 | -$58.70 K | -$58.70 K(+32.2%) |
| Sept 2008 | - | -$44.40 K(+6.0%) |
| June 2008 | - | -$41.90 K(+55.8%) |
| Mar 2008 | - | -$26.90 K |
FAQ
- What is Iovance Biotherapeutics annual retained earnings?
- What is the all time high annual retained earnings for Iovance Biotherapeutics?
- What is Iovance Biotherapeutics annual retained earnings year-on-year change?
- What is Iovance Biotherapeutics quarterly retained earnings?
- What is the all time high quarterly retained earnings for Iovance Biotherapeutics?
- What is Iovance Biotherapeutics quarterly retained earnings year-on-year change?
What is Iovance Biotherapeutics annual retained earnings?
The current annual retained earnings of IOVA is -$2.01 B
What is the all time high annual retained earnings for Iovance Biotherapeutics?
Iovance Biotherapeutics all-time high annual retained earnings is -$58.70 K
What is Iovance Biotherapeutics annual retained earnings year-on-year change?
Over the past year, IOVA annual retained earnings has changed by -$444.04 M (-28.31%)
What is Iovance Biotherapeutics quarterly retained earnings?
The current quarterly retained earnings of IOVA is -$2.31 B
What is the all time high quarterly retained earnings for Iovance Biotherapeutics?
Iovance Biotherapeutics all-time high quarterly retained earnings is -$26.90 K
What is Iovance Biotherapeutics quarterly retained earnings year-on-year change?
Over the past year, IOVA quarterly retained earnings has changed by -$410.00 M (-21.62%)